Breaking News, Financial News

Hospira 3Q

Hospira

3Q Revenues: $838 million (+30%)

3Q Earnings: $59 million (+6%)

YTD Revenues: $2.5 billion (+26%)

YTD Earnings: $61 million (-68%)

Comments: Integration of Mayne Pharma helped drive revenue growth, while restructuring costs drove down earnings. Injectable Pharmaceutical Contract Manufacturing revenues were down 12% to $33.5 million in 3Q and down 20% to $111.6 million YTD.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters